This Article Full Text (PDF) References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in ISI Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via ISI Web of Science (9) Citing Articles via Google Scholar Google Scholar Articles by Gillman, S. A. Articles by Newman, K. Search for Related Content PubMed PubMed Citation Articles by Gillman, S. A. Articles by Newman, K. Social Bookmarking                   What's this?

One-Year Trial on Safety and Normal Linear Growth with Flunisolide HFA in Children with Asthma

Division of Allergy, Asthma, and Immunology, Children's Hospital of Orange County, Orange, hypothalamic pituitary axis California

Robert Anolik, MD

Blue Bell, Pennsylvania

Eric Schenkel, MD

Valley Clinical Research Center, Easton, Pennsylvania

Kenneth Newman, MD

Department of Respiratory Products, Forest Laboratories, Inc., New York, NY

Flunisolide hydrofluoroalkane (HFA) has efficacy equivalent to that of flunisolide chlorofluorocarbon (CFC) at one third the dose of the CFC formulation, a reduction from 250 pg/puff for flunisolide CFC to 85 pg/puff for flunisolide HFA. Flunisolide HFA delivers a smaller particle size (1.2 pim) in solution, resulting in improved lung deposition as compared with flunisolide CFC (3.8 pm), which is delivered in suspension. An added built-in spacer has reduced oropharyngeal deposition that may result in fewer adverse events and make it easier to use. The objective of this study was to compare the year-long safety of flunisolide HFA (daily dosage 340 pg) with that of CFC beclomethasone dipropionate (BDP) (daily dosage 336 pg) and cromolyn sodium (daily dosage 6,400 pg) in children 4-11 years old with mild-to-moderate asthma. The effects of these drugs on linear growth and growth velocity were also compared. The study was a 1-year open-label, parallel-group trial. Changes in physical examinations (including growth), adverse events, vital signs, electrocardiograms, cosyntropin stimulation tests, mouth and throat cultures for Candida albicans, and laboratory findings were analyzed. Patients 4-5 years old received flunisolide HFA only. In total, 235 children were evaluated (152 receiving flunisolide HFA, 39 BDP, and 44 cromolyn). The incidence of adverse events was comparable among treatment groups; most were mild or moderate and considered unrelated to treatment. Among patients 6-11 years old, mean changes from baseline height at week 52 were 6.2 cm for the flunisolide HFA and cromolyn groups and 5.1 cm for the BDP group. Thus growth in children receiving flunisolide HFA was unaffected by 1 year of treatment. Changes from baseline in other parameters, including response to cosyntropin stimulation, were insignificant and similar among the 3 treatment groups. At the dosages studied, and following 1 year of treatment, flunisolide HFA with its small particle size and built-in spacer is safe and well tolerated in children 4-11 years old. There are no adverse effects associated with HFA, including linear growth in children 6-11 years old when compared with BDP and cromolyn sodium.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				B. Q. Lanier Use of Intranasal Corticosteroids in the Management of Congestion and Sleep Disturbance in Pediatric Patients With Allergic Rhinitis Clinical Pediatrics, June 1, 2008; 47(5): 435 - 445. [Abstract] [PDF]

				D. P. Skoner, J. Maspero, D. Banerji, and and the Ciclesonide Pediatric Growth Study Group Assessment of the Long-term Safety of Inhaled Ciclesonide on Growth in Children With Asthma Pediatrics, January 1, 2008; 121(1): e1 - e14. [Abstract] [Full Text] [PDF]